You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MSI-H

Showing 26 - 50 of 2,526
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Colorectal Cancer Trial in Beijing (IBI310 (anti-CTLA-4 antibody), Sintilimab(anti-PD-1 antibody))

Active, not recruiting
  • Colorectal Cancer
  • IBI310 (anti-CTLA-4 antibody)
  • Sintilimab(anti-PD-1 antibody)
  • Beijing, China
    Beijing cancer hospital
Sep 15, 2022

MSI-H Colorectal Cancer Trial (colorectal resection)

Completed
  • MSI-H Colorectal Cancer
  • colorectal resection
  • (no location specified)
May 22, 2023

Anti-PD-1 Antibody, Radiotherapy, Rectal Cancer Trial in Chengdu (Sintilimab, Hypofractionated Radiotherapy)

Recruiting
  • Anti-PD-1 Antibody
  • +4 more
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
Apr 25, 2022

Solid Tumor Trial in Beijing (KN035)

Recruiting
  • Solid Tumor
  • KN035
  • Beijing, Beijing, China
    Peking University Cancer Hospital, Peking University
Apr 5, 2022

Colorectal Cancer, Microsatellite Instability High Trial in Guangzhou (PD-1 inhibitor plus VEGF inhibitors)

Recruiting
  • Colorectal Cancer
  • Microsatellite Instability High
  • PD-1 inhibitor plus VEGF inhibitors
  • Guangzhou, Guangdong, China
    651 Dongfeng Road East
May 27, 2022

Serplulimab,Gastric Cancer, Adjuvant Therapy Trial in Shanghai (Serplulimab, Docetaxel, S1)

Recruiting
  • Serplulimab,Gastric Cancer, Adjuvant Therapy
  • Shanghai, China
    Zhang Zizhen
Mar 3, 2023

Recurrent/Metastatic Gastric Cancer Trial in Seoul (Nivolumab, Paclitaxel)

Completed
  • Recurrent/Metastatic Gastric Cancer
  • Nivolumab, Paclitaxel
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Sep 9, 2022

Digestive System Cancers Trial in Beijing (KN046, Regorafenib, Apatinib)

Recruiting
  • Digestive System Cancers
  • Beijing, China
    Peking University Cancer Hospital
Oct 25, 2023

Metastatic Colorectal Cancer Trial in China (HX008, Investigator's Choice Chemotherapy)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • HX008
  • Investigator's Choice Chemotherapy
  • Hefei, Anhui, China
  • +9 more
Dec 8, 2022

Solid Tumors, Identified by NGS, PCR or IHC Trial in United States (Pembrolizumab)

Recruiting
  • Solid Tumors
  • Identified by NGS, PCR or IHC
  • Basking Ridge, New Jersey
  • +6 more
Oct 7, 2022

Head and Neck Tumors, MSI-H Cancer, Melanoma Trial (Tiragolumab and atezolizumab)

Not yet recruiting
  • Head and Neck Neoplasms
  • +2 more
  • Tiragolumab and atezolizumab
  • (no location specified)
Aug 1, 2022

Renal Cell Carcinoma, Bladder Cancer, MSI-H Cancer Trial in Paris (Arterial Doppler for Flow Mediated Reserve measurement)

Recruiting
  • Renal Cell Carcinoma
  • +3 more
  • Arterial Doppler for Flow Mediated Reserve measurement
  • Paris, France
    INstitut Mutualiste Montsouris
Aug 29, 2023

DMMR Colorectal Cancer, MSI-H Colorectal Cancer, Locally Advanced Colorectal Cancer Trial in Guangzhou (drug, radiation,

Recruiting
  • DMMR Colorectal Cancer
  • +2 more
  • PD-1 Antibody
  • +4 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 22, 2021

Melanoma, Hepatocellular Carcinoma (HCC), Renal Cell Carcinoma (RCC) Trial (INCB 99280 with Ipilimumab)

Not yet recruiting
  • Melanoma
  • +5 more
  • INCB 99280 with Ipilimumab
  • (no location specified)
Jun 9, 2023

Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors Trial in Baltimore (Nivolumab, Relatlimab)

Recruiting
  • Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy
  • MSI-H Tumors
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
Mar 14, 2022

Immunotherapy, Adjuvant Therapy, Colon Cancer Trial in Tianjin (Tirelizumab)

Recruiting
  • Immunotherapy
  • +3 more
  • Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Jul 11, 2021

Colorectal Cancer Trial in Essen (Atezolizumab)

Recruiting
  • Colorectal Cancer
  • Essen, Germany
    Westdeutsches Tumorzentrum
Feb 14, 2022

MSI-H Advanced Colorectal Cancer Trial in Tianjin (Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen)

Recruiting
  • MSI-H Advanced Colorectal Cancer
  • Pembrolizumab (PD-1 Inhibitor) Combined With Bevacizumab and FOLFIRI Regimen
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute & Hospital
Sep 3, 2021

Colorectal Carcinoma Trial in Beijing (Toripalimab, Bevacizumab, Irinotecan)

Recruiting
  • Colorectal Carcinoma
  • Beijing, Beijing, China
    Peking University Cancer Hospital and Institute
Jul 31, 2021

Melanoma Stage IV, Unresectable Melanoma, NSCLC Stage IV Trial in Ramat Gan (Fecal Microbial Transplantation by capsules)

Recruiting
  • Melanoma Stage IV
  • +2 more
  • Fecal Microbial Transplantation by capsules
  • Ramat Gan, Israel
    Sheba Medical Center
Aug 9, 2021

Rectal Cancer Trial in Guangzhou (watch and wait)

Recruiting
  • Rectal Cancer
  • watch and wait
  • Guangzhou, Guangdong, China
    Sun Yatsen University
May 10, 2021

Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage II Gastroesophageal Junction

Not yet recruiting
  • Clinical Stage I Gastric Cancer AJCC v8
  • +9 more
  • Atezolizumab
  • +12 more
  • (no location specified)
Apr 26, 2023

Colorectal Cancer Trial in China (Tislelizumab)

Recruiting
  • Colorectal Cancer
  • Bengbu, Anhui, China
  • +7 more
Sep 13, 2022

MSI-H Solid Malignant Tumor Trial in China (HLX10)

Recruiting
  • MSI-H Solid Malignant Tumor
  • Hefei, Anhui, China
  • +32 more
Oct 26, 2022

Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Tumor Trial in Australia (Ipilimumab,

Recruiting
  • Advanced Biliary Tract Cancer
  • +3 more
  • Albury, New South Wales, Australia
  • +11 more
Oct 31, 2022